Meeting objectives and introduction
David Maloney & Frederick Locke

Welcome to the solid tumors day
Kedar Kirtane & Sarah Nikiforow

Keynote talk 1
How solid CAR-T targeting has evolved: Prasad Adusumilli

Session 1: CARs targeting cell surface proteins (part I)
Chairs: Susanne Baumeister & TBC

• DLL3-CAR-T for SCLC: Adam Schoenfeld
• GCC19 CAR-T therapy for refractory colorectal cancer: Overcoming challenges in expansion and persistence: Benjamin Schlechter
• Updates on logic-gated CAR T-cell therapies in pancreatic cancer: Joel Randolph Hecht
• Talk title TBC (LYL797): Jennifer Specht

Panel discussion

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Joel Randolph Hecht & TBC

• Talk title TBC (BNT211): TBC
• CAR T cells for relapsed/refractory neuroblastoma: Susanne Baumeister
• Talk title TBC (FSHR-targeting CAR T): Monica Avila

Panel discussion

Break

Session 3: T-cell engagers and TCRs
Chairs: Kedar Kirtane & Susanne Baumeister

• Talk title TBC (afamicel): Mihaela Druta
• Immunologic targeting of undruggable TP53 hotspot mutations through T cell receptor gene therapy:
  Mike Gormally
• Targeting PRAME with TCR T cells first in melanoma then beyond: Jason Luke
• Talk title TBC (Tarlatamab): TBC

Panel discussion

Lunch

Session 4: TILs across solid tumors
Chairs: Allison Betof Warner & Claire Roddie

• Talk title TBC: Benjamin Creelan
• Talk title TBC: Michael Poch
• Optimizing TIL therapy for melanoma & beyond: Allison Betof Warner

Panel discussion

Session 5: Novel technologies in solid tumors
Chairs: Sarah Nikiforow & Kedar Kirtane 

• Talk title TBC (TanCAR-T): Brian Choi
• Genome-edited anti-GPC3 CAR for hepatoma: Marco Davila
• Engineering myeloid cells for solid tumors and fibrosis: CARs and beyond: Michael Klichinsky
• Cell and gene therapy: Current status and future directions – An industry perspective: Will Go
• Advancing T cell therapies for solid cancers: Saul Priceman

Panel discussion

Break

Session 6: T-cell engagers and CARs in CLL
Chairs: David Maloney & Saar Gill

• Optimizing liso-cel in CLL: Sequencing and combination strategies: Mazyar Shadman
• Why bispecific antibodies may be the path forward in CLL: Alexey Danilov

Panel discussion

Session 7: CAR-T in ALL
Chairs: Claire Roddie & Saar Gill

• Talk title TBC (obecabtagene autoleucel): Claire Roddie
• Talk title TBC (brexucabtagene autoleucel): Bijal Shah
• CD19/CD22 CAR-T: Noelle Frey
• SCRI‐CAR19 with CD19 T‐APC to prolong CAR T cell persistence: Rebecca Gardner
• Improving clinical activity of CD5 CART in T-ALL: Maksim Mamonkin

Panel discussion

Day 1 conclusions

Welcome reception

Welcome to Day 2
Sarah Nikiforow & Yi Lin

Keynote talk 2
Frontiers in CAR-T cell therapy for autoimmune diseases: David Porter

Session 8: CAR therapy for autoimmune rheumatic disorders
Chairs: David Porter & TBC

• Talk title TBC (NKX019): David Shook
• Talk title TBC (BMS-986353): Lazaros Lekakis
• Talk title TBC (KYV-101 – dermatomyositis): Everett Meyer

Panel discussion

Session 9: CAR therapy for neurological autoimmune diseases
Chairs: David Porter & Everett Meyer

• Talk title TBC: Saurabh Sahiya
• Antigen-specific treatment of myasthenia: Development of rat chimeric autoantibody receptor (CAAR) T cells to treat experimental autoimmune MuSK myasthenia: David Richman
• State of the art with CAR therapy in MG: Ali Habib

Panel discussion

 

Break

Session 10: How do we integrate autoimmune diseases into cell therapy centres?
Chairs: David Maloney & Sarah Nikiforow

Discussants: Frederick Locke, Everett Meyer, David Porter, Claire Roddie

Session 11: Translational studies with T-cell engagers and CARs   
Chairs: Yi Lin & TBC

• Genomic determinants of resistance to anti BCMA and GPRC5D therapies: Francesco Maura
• Metabolic fitness in CAR-T cells from earlier in the treatment course: Ciara Freeman

Panel discussion

Keynote talk 3
Accelerating CAR T-cell therapeutics with small molecules: Michael Hudecek

Lunch

Session 12: T-cell engagers for multiple myeloma
Chairs: Saad Usmani & TBC

• Talk title TBC (cevostamab): Rakesh Popat
• Talk title TBC (teclistamab): Tom Martin
• Talk title TBC (talquetamab): TBC
• Talk title TBC (JNJ-79635322): Sham Mailankody

Panel discussion

Session 13: CAR therapy for multiple myeloma
Chairs: Adam Sperling & TBC

• CAR-T cells in multiple myeloma: The evolving use of cilta-cel and ide-cel: Adam Sperling
• Phase I / II summary of anito-cel for relapsed/refractory MM: Matthew Frigault
• Talk title TBC (BMS-986393): Susan Bal
• BCMA CAR-T clash of the Titans: Idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: Doris Hansen

Panel discussion

Break

Session 14: CAR therapy should come before T-cell engagers in multiple myeloma treatment sequencing
Chairs: Yi Lin & Doris Hansen

• For: Krina Patel
• Against: Sham Mailankody

Panel discussion

Session 15: Different approaches to CAR production in lymphoma
Chairs: David Maloney & Caron Jacobson

• Talk title TBC (VivoVec platform): TBC
• Point-of-care manufacturing with Canadian-made CD19 CART, CLIC-1901: Natasha Kekre
• Talk title TBC (GLPG5101): TBC
• Interim result multicenter Phase II trial of zamtocabtagene autoleucel, an non-cryopreserved
  anti-CD20/anti-CD19 CAR T cell product for relapsed, refractory DLBCL: Nirav Shah

Panel discussion

Day 2 conclusions

Faculty Dinner

Welcome to Day 3
Caron Jacobson & Frederick Locke

Session 16: Long-term follow-up and outcomes with CARs
Chairs: David Miklos & TBC

• Risk stratification and secondary malignancies: Kai Rajeski
• Long-term complications after CAR T-cell therapy: Michael Jain
• Catch me if you can: Lymphoma resistance to CAR T immunotherapy: Marco Ruella
• Enhancing CAR T-cell activity and persistence with CAR-enhancer therapeutics: Mohamad Rashidian

Panel discussion

Session 17: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & Marion Subklewe

• Back to the bench: Rethinking CAR T for AML: Marion Subklewe
• Allogeneic, off-the-shelf, CAR T cells for AML: CB-012: Jae Park
• Treatment of JMML and CMML with CLL-1 CAR-T cells +/- trametinib: Elliot Stieglitz
• Talk title TBC (CALR bispecific): Andrew Kuykendall

Panel discussion

Break

Session 18: What are the current challenges with CAR T in lymphoma and how can we address them?
Chairs: Caron Jacobson & David Miklos

• Barriers: Why is CAR T-cell therapy not reaching its potential in heme malignancies?: Jason Westin
• Sequencing novel treatment options in lymphoma: Gloria Iacoboni
• Talk title TBC (perspective 3): Frederick Locke

Panel discussion

Session 19: T-cell engagers and CARs in lymphomas
Chairs: Tycel Phillips & TBC                                                                                                                                                     

• Update on CB-010/allogeneic anti-CD19 CAR-T cell therapy: Mehdi Hamadani
• Bispecifics in lymphoma: Moving beyond CD20 targeting: Krish Patel
• Frontline & second-line DLBCL treatments – where are we in 2025?: Matt Lunning
• Fixed-duration treatment with epcoritamab: Alexey Danilov
• Mosunetuzumab + polatuzumab vedotin: Jennifer Crombie

Panel discussion

Keynote talk 4
Moving bispecifics and CAR T-cell therapies into the community setting: Tara Graff

Session 20: How to get CAR T-cell therapy into the community setting?
Chairs: Elizabeth Budde & TBC   

Discussants: Tara Graff, John Kuruvilla, TBC

Meeting conclusions